PT  - JOURNAL ARTICLE
AU  - Chen, Xiangyu
AU  - Li, Ren
AU  - Pan, Zhiwei
AU  - Qian, Chunfang
AU  - Yang, Yang
AU  - You, Renrong
AU  - Zhao, Jing
AU  - Liu, Pinghuang
AU  - Gao, Leiqiong
AU  - Li, Zhirong
AU  - Huang, Qizhao
AU  - Xu, Lifan
AU  - Tang, Jianfang
AU  - Tian, Qin
AU  - Yao, Wei
AU  - Hu, Li
AU  - Yan, Xiaofeng
AU  - Zhou, Xinyuan
AU  - Wu, Yuzhang
AU  - Deng, Kai
AU  - Zhang, Zheng
AU  - Qian, Zhaohui
AU  - Chen, Yaokai
AU  - Ye, Lilin
TI  - Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
AID  - 10.1101/2020.04.06.20055475
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.06.20055475
4099  - http://medrxiv.org/content/early/2020/04/11/2020.04.06.20055475.short
4100  - http://medrxiv.org/content/early/2020/04/11/2020.04.06.20055475.full
AB  - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel corona virus disease (COVID-19). To date, no prophylactic vaccines or approved therapeutic agents are available for preventing and treating this highly transmittable disease. Here we report two monoclonal antibodies (mAbs) cloned from memory B cells of patients recently recovered from COVID-19, and both mAbs specifically bind to the spike (S) protein of SARS-CoV-2, block the binding of receptor binding domain (RBD) of SARS-CoV-2 to human angiotensin converting enzyme 2 (hACE2), and effectively neutralize S protein-pseudotyped virus infection. These human mAbs hold the promise for the prevention and treatment of the ongoing pandemic of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Natural Science Fund for Distinguished Young Scholars (No. 31825011 to L.Y.) and the Chongqing Special Research Project for Novel Coronavirus Pneumonia Prevention and Control (No. cstc2020jscx-2 to L.Y.; No. cstc2020jscx-fyzx0074 to Y.C.; cstc2020jscx-fyzx0135 to Y.C.).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data in the manuscript are of availability.